155 related articles for article (PubMed ID: 30241105)
41. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
42. Relation between increased fetal nuchal translucency thickness and chromosomal defects.
Kagan KO; Avgidou K; Molina FS; Gajewska K; Nicolaides KH
Obstet Gynecol; 2006 Jan; 107(1):6-10. PubMed ID: 16394033
[TBL] [Abstract][Full Text] [Related]
43. A mixture model of nuchal translucency thickness in screening for chromosomal defects.
Wright D; Kagan KO; Molina FS; Gazzoni A; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Apr; 31(4):376-83. PubMed ID: 18383462
[TBL] [Abstract][Full Text] [Related]
44. Screening for trisomy 21 based on maternal age, nuchal translucency measurement, first trimester biochemistry and quantitative and qualitative assessment of the flow in the DV - the assessment of efficacy.
Czuba B; Zarotyński D; Dubiel M; Borowski D; Węgrzyn P; Cnota W; Reska-Nycz M; Mączka M; Wielgoś M; Sodowski K; Serafin D; Kubaty A; Bręborowicz GH
Ginekol Pol; 2017; 88(9):481-485. PubMed ID: 29057433
[TBL] [Abstract][Full Text] [Related]
45. Sphenofrontal distance in euploid and aneuploid fetuses.
Abele H; Sonek J; Goldschmid D; Wagner P; Hoopmann M; Kagan KO
Ultrasound Obstet Gynecol; 2017 Aug; 50(2):187-191. PubMed ID: 27550089
[TBL] [Abstract][Full Text] [Related]
46. Nasal bone in screening for T21 at 11-13 + 6 weeks of gestation - a multicenter study.
Węgrzyn P; Czuba B; Serafin D; Cnota W; Dubiel M; Mączka M; Zarotyński D; Ruci A; Wielgoś M; Sodowski K; Borowski D
Ginekol Pol; 2016; 87(11):751-754. PubMed ID: 27958633
[TBL] [Abstract][Full Text] [Related]
47. [Fetal hepatic artery flow assessment in prenatal diagnostics--a review of the literature].
Lipa M; Samaha RB; Borowski D; Wielgoś M; Wegrzyn P
Ginekol Pol; 2014 Jul; 85(7):532-5. PubMed ID: 25118506
[TBL] [Abstract][Full Text] [Related]
48. [Screening for aneuploidy by first trimester nuchal translucency measurement: results from a prospective trial including 1980 cases in a single center in Switzerland].
Tercanli S; Holzgreve W; Batukan C; Gerber A; Ermis H; Miny P
Ultraschall Med; 2002 Feb; 23(1):22-6. PubMed ID: 11842368
[TBL] [Abstract][Full Text] [Related]
49. First-trimester ultrasound screening for trisomy 21 based on maternal age, fetal nuchal translucency, and different methods of ductus venosus assessment.
Wagner P; Sonek J; Klein J; Hoopmann M; Abele H; Kagan KO
Prenat Diagn; 2017 Jul; 37(7):680-685. PubMed ID: 28493464
[TBL] [Abstract][Full Text] [Related]
50. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH
Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
[TBL] [Abstract][Full Text] [Related]
51. Application of an individualized nomogram in first-trimester screening for trisomy 21.
Sun Y; Zhang L; Dong D; Li X; Wang J; Yin C; Poon LC; Tian J; Wu Q
Ultrasound Obstet Gynecol; 2021 Jul; 58(1):56-66. PubMed ID: 32438493
[TBL] [Abstract][Full Text] [Related]
52. What is the importance of second-trimester "soft markers" for trisomy 21 after an 11- to 14-week aneuploidy screening scan?
Bromley B; Shipp TD; Lyons J; Groszmann Y; Navathe RS; Benacerraf BR
J Ultrasound Med; 2014 Oct; 33(10):1747-52. PubMed ID: 25253820
[TBL] [Abstract][Full Text] [Related]
53. Quantitative and qualitative Ductus Venosus blood flow evaluation in the screening for Trisomy 18 and 13 - suitability study.
Czuba B; Nycz-Reska M; Cnota W; Jagielska A; Wloch A; Borowski D; Wegrzyn P
Ginekol Pol; 2020; 91(3):144-148. PubMed ID: 32266955
[TBL] [Abstract][Full Text] [Related]
54. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
[TBL] [Abstract][Full Text] [Related]
55. Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy.
Brizot ML; Snijders RJ; Butler J; Bersinger NA; Nicolaides KH
Br J Obstet Gynaecol; 1995 Feb; 102(2):127-32. PubMed ID: 7538782
[TBL] [Abstract][Full Text] [Related]
56. Umbilical cord diameter at 11-14 weeks of gestation: relationship to nuchal translucency, ductus venous blood flow and chromosomal defects.
Axt-Fliedner R; Schwarze A; Kreiselmaier P; Krapp M; Smrcek J; Diedrich K
Fetal Diagn Ther; 2006; 21(4):390-5. PubMed ID: 16757918
[TBL] [Abstract][Full Text] [Related]
57. Further insights into diastolic dysfunction in first-trimester trisomy-21 fetuses.
Mula R; Grande M; Bennasar M; Crispi F; Borobio V; Martinez JM; Gratacos E; Borrell A
Ultrasound Obstet Gynecol; 2015 Feb; 45(2):205-10. PubMed ID: 24706444
[TBL] [Abstract][Full Text] [Related]
58. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
Spencer K; Nicolaides KH
BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
[TBL] [Abstract][Full Text] [Related]
59. Detection of triploidy at 11-14 weeks' gestation: a cohort study of 198 000 pregnant women.
Engelbrechtsen L; Brøndum-Nielsen K; Ekelund C; Tabor A; Skibsted L;
Ultrasound Obstet Gynecol; 2013 Nov; 42(5):530-5. PubMed ID: 23494847
[TBL] [Abstract][Full Text] [Related]
60. [Ultrasound screening for Down syndrome and other chromosomal abnormalities by fetal nuchal translucency measurement between 11-14 weeks of gestation].
Dimitrova V; Markov D; Chernev T; Karag'ozova Zh; Mazneĭkova V; Andonova S; Vŭzharova R
Akush Ginekol (Sofiia); 2005; 44(1):32-7. PubMed ID: 15853009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
